Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Development of gene therapies—lessons from nusinersen

Gene Therapy volume 24, pages 527–528 (2017)Cite this article

Subjects

Abstract

The nusinersen development and approval process provide important lessons regarding the pathway to marketing approval for gene therapies. These lessons emphasize rigorous clinical trial design, flexibility in trial design and analysis, a collaborative effort with regular communications between the drug developer and the Food and Drug Administration (FDA), and use of FDA’s expedited programs. These lessons are critical to the development of gene therapies for the treatment of serious or life-threatening rare diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Nusinersen (SPINRAZA) FDA reviews and label. 2016. Available at:http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209531Orig1s000TOC.cfm.

  2. FDA Draft Guidance for Industry: Target Product Profile - A Strategic Development Process Tool. 2007. Available at:www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080593.pdf.

  3. FDA Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics. 2014. Available at:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf.

Download references

Author information

Authors and Affiliations

  1. Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA

    L Xu, I Irony & W W Bryan

  2. Division of Neurology Products, Office of New Drugs, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA

    B Dunn

Authors
  1. L Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Irony
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W W Bryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W W Bryan.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, L., Irony, I., Bryan, W. et al. Development of gene therapies—lessons from nusinersen. Gene Ther 24, 527–528 (2017). https://doi.org/10.1038/gt.2017.64

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2017.64

This article is cited by

Search

Advanced search

Quick links